Equities research analysts at Maxim Group assumed coverage on shares of Nasus Pharma (NYSEAMERICAN:NSRX – Get Free Report) in a note issued to investors on Friday, Benzinga reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Maxim Group‘s price objective would suggest a potential upside of 115.78% from the stock’s current price.
Nasus Pharma Price Performance
NSRX opened at $3.24 on Friday. The stock has a fifty day moving average price of $3.59 and a 200 day moving average price of $3.66. Nasus Pharma has a 1 year low of $1.98 and a 1 year high of $9.50.
Nasus Pharma (NYSEAMERICAN:NSRX – Get Free Report) last issued its quarterly earnings data on Monday, August 17th. The company reported ($0.27) earnings per share for the quarter. Research analysts expect that Nasus Pharma will post -0.84 earnings per share for the current fiscal year.
About Nasus Pharma
Nasus Pharma Ltd. is a specialty pharmaceutical company focused on developing intranasal powder-based medicines. Its proprietary platform is designed to deliver drug therapies through the nose, with the potential to support rapid administration without the need for injections or other conventional delivery methods.
The company’s development efforts are directed toward acute and emergency-care applications, including treatments for conditions in which rapid drug delivery may be important.
See Also
- Five stocks we like better than Nasus Pharma
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
- SaaS-Pocalypse II: Is ServiceNow’s Sell-Off Another Buying Opportunity?
- Robinhood Stock Is Down Nearly 37%—So Why Is Wall Street Still So Bullish?
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
